Author [ Title] Type Year
Filters: Author is McAllister, Sandra S [Clear All Filters]
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies. PLoS One. 2018;13(6):e0198790..
Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression. Cancer Res. 2016;76(10):2932-2943..